Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of ($0.51), $0.05 better than the analyst estimate of ($0.56).

2017 Financial Guidance

Revenues from milestones under the AbbVie agreement for 2017 are expected to be $30 million. Ongoing operating expenses for 2017 should approximate $230 million to $240 million, exclusive of the $30 million up-front fee for in-licensing opicapone. The 2017 anticipated expenses include an estimated $40 million of share-based compensation expense. The increase in expected expenses is primarily related to anticipated commercialization activities for INGREZZA in tardive dyskinesia.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.